Gabriel Hortobagyi, MD, MACP, FASCO

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

A panel of breast oncologists highlight exciting treatment strategies being explored in clinical trials to help address treatment limitations in HR+/HER2- metastatic breast cancer.

The relevance of PIK3CA mutations in terms of the pathophysiology of HR-positive metastatic breast cancer, and lessons learned in practice and via clinical studies in terms of sequencing therapy with PI3K inhibitors.

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.